None
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=A104608229
Rojin Park (Soonchunhyang University Seoul Hospital)
2015
English
KCI등재,SCOPUS,ESCI
학술저널
1-2(2쪽)
0
0
상세조회0
다운로드참고문헌 (Reference)
1 Li J, "Thrombocytopenia caused by the development of antibodies to thrombopoietin" 98 : 3241-3248, 2001
2 McMillan R, "Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP" 103 : 1364-1369, 2004
3 Nurden AT, "New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura" 373 : 1562-1569, 2009
4 Cines DB, "How I treat idiopathic thrombocytopenic purpura (ITP)" 106 : 2244-2251, 2005
5 Cheng G., "Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile" 3 : 155-164, 2012
6 Bussel JB, "Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura" 357 : 2237-2247, 2007
7 Kuter DJ, "Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial" 371 : 395-403, 2008
8 Yeo-Kyeoung Kim, "Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia" 대한혈액학회 50 (50): 19-25, 2015
9 Saleh MN, "EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study" 121 : 537-545, 2013
10 Tomiyama Y, "A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia" 10 : 799-806, 2012
1 Li J, "Thrombocytopenia caused by the development of antibodies to thrombopoietin" 98 : 3241-3248, 2001
2 McMillan R, "Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP" 103 : 1364-1369, 2004
3 Nurden AT, "New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura" 373 : 1562-1569, 2009
4 Cines DB, "How I treat idiopathic thrombocytopenic purpura (ITP)" 106 : 2244-2251, 2005
5 Cheng G., "Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile" 3 : 155-164, 2012
6 Bussel JB, "Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura" 357 : 2237-2247, 2007
7 Kuter DJ, "Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial" 371 : 395-403, 2008
8 Yeo-Kyeoung Kim, "Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia" 대한혈액학회 50 (50): 19-25, 2015
9 Saleh MN, "EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study" 121 : 537-545, 2013
10 Tomiyama Y, "A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia" 10 : 799-806, 2012
Is cord blood worth saving for public or private banking?
A case of pediatric ALL with t(16;21)(p11.2;q22) and FUS-ERG rearrangement
Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
학술지 이력
연월일 | 이력구분 | 이력상세 | 등재구분 |
---|---|---|---|
2023 | 평가예정 | 해외DB학술지평가 신청대상 (해외등재 학술지 평가) | |
2020-01-01 | 평가 | 등재학술지 유지 (해외등재 학술지 평가) | |
2013-11-22 | 학술지명변경 | 한글명 : 대한혈액학회지 -> Blood Research외국어명 : The Korean Journal of Hematology -> Blood Research | |
2012-02-01 | 평가 | SCOPUS 등재 (등재유지) | |
2011-01-01 | 평가 | 등재학술지 유지 (등재유지) | |
2009-01-01 | 평가 | 등재학술지 유지 (등재유지) | |
2007-01-01 | 평가 | 등재학술지 유지 (등재유지) | |
2006-04-06 | 학술지명변경 | 외국어명 : 미등록 -> The Korean Journal of Hematology | |
2004-01-01 | 평가 | 등재학술지 선정 (등재후보2차) | |
2003-01-01 | 평가 | 등재후보 1차 PASS (등재후보1차) | |
2002-01-01 | 평가 | 등재후보학술지 유지 (등재후보1차) | |
1999-07-01 | 평가 | 등재후보학술지 선정 (신규평가) |
학술지 인용정보
기준연도 | WOS-KCI 통합IF(2년) | KCIF(2년) | KCIF(3년) |
---|---|---|---|
2016 | 0.08 | 0.08 | 0.12 |
KCIF(4년) | KCIF(5년) | 중심성지수(3년) | 즉시성지수 |
0.13 | 0.12 | 0.339 | 0.02 |